Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 22Terminated 12Unknown 9Recruiting 9Active not recruiting 5Withdrawn 3Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Breast 1

Conditions

Pancreatic Neoplasms 20Urinary Bladder Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 7Nasopharyngeal Carcinoma 6Biliary Tract Neoplasms 6Nasopharyngeal Neoplasms 5Cholangiocarcinoma 4Ovarian Neoplasms 3Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Recurrence 2Pancreatic Cancer Resectable 2Neoplasm Metastasis 2Lymphoma, Extranodal NK-T-Cell 2Thyroid Neoplasms 1Rhabdoid Tumor 1Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma 1Rare Tumour 1Pancreatic cancer, adult 1Pancreatic Cystic Neoplasm 1Pancreatic Cancer Non-resectable 1PDAC - Pancreatic Ductal Adenocarcinoma 1Mibc 1Melanoma 1Lung Neoplasms 1Lung Diseases, Interstitial 1Locally Advanced Pancreatic Cancer 1Liver Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × Gemcitabine × Clear all
NCT07406542 2026-02-12

A Phase III Study of SYS6010 Versus Chemotherapy in HER2-Negative, EGFR-Positive Recurrent or Metastatic Breast Cancer

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 3 Not yet recruiting
400 enrolled
Breast

Breast Neoplasms, Recurrence

NCT06892431 2025-03-25

JMT101 Combined With Mitoxantrone Liposome for Nasopharyngeal Cancer

Shanghai JMT-Bio Inc.

Phase 2 Not yet recruiting
150 enrolled
Head & Neck

Nasopharyngeal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡